Teladoc Health (NYSE:TDOC) Lowered to “Neutral” at Citigroup

Teladoc Health (NYSE:TDOCGet Rating) was downgraded by investment analysts at Citigroup from a “buy” rating to a “neutral” rating in a research report issued on Thursday, Marketbeat Ratings reports. They presently have a $43.00 price objective on the health services provider’s stock, down from their previous price objective of $115.00. Citigroup’s target price suggests a potential upside of 8.97% from the stock’s previous close.

A number of other research firms also recently weighed in on TDOC. Jefferies Financial Group decreased their price target on Teladoc Health from $113.00 to $82.00 and set a “hold” rating on the stock in a research note on Monday, February 7th. Evercore ISI decreased their target price on Teladoc Health from $90.00 to $70.00 and set an “inline” rating on the stock in a research report on Wednesday, February 23rd. Argus upgraded Teladoc Health from a “hold” rating to a “buy” rating and set a $95.00 target price on the stock in a research report on Thursday, March 3rd. Stifel Nicolaus decreased their target price on Teladoc Health from $83.00 to $74.00 and set a “hold” rating on the stock in a research report on Wednesday, February 23rd. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Teladoc Health from $81.00 to $78.00 and set a “hold” rating on the stock in a research report on Thursday, February 24th. One investment analyst has rated the stock with a sell rating, eighteen have issued a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $96.79.

Shares of NYSE:TDOC traded up $2.32 during trading on Thursday, reaching $39.46. The company had a trading volume of 15,603,538 shares, compared to its average volume of 6,254,720. The firm has a market capitalization of $6.36 billion, a price-to-earnings ratio of -0.82 and a beta of 0.82. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.70 and a quick ratio of 3.48. The stock’s fifty day moving average price is $63.71 and its 200 day moving average price is $87.25. Teladoc Health has a fifty-two week low of $28.75 and a fifty-two week high of $174.32.

Teladoc Health (NYSE:TDOCGet Rating) last released its earnings results on Wednesday, April 27th. The health services provider reported ($41.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($41.00). Teladoc Health had a negative net margin of 321.94% and a negative return on equity of 1.90%. During the same period last year, the business posted $0.13 earnings per share. On average, equities analysts anticipate that Teladoc Health will post -2.04 EPS for the current fiscal year.

In other Teladoc Health news, insider Adam C. Vandervoort sold 3,513 shares of the firm’s stock in a transaction that occurred on Thursday, March 3rd. The stock was sold at an average price of $70.24, for a total transaction of $246,753.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Stephany Verstraete sold 2,858 shares of the firm’s stock in a transaction that occurred on Thursday, March 3rd. The shares were sold at an average price of $70.24, for a total value of $200,745.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,842 shares of company stock worth $1,042,502. Company insiders own 1.55% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. ARK Investment Management LLC grew its position in shares of Teladoc Health by 2.9% in the 1st quarter. ARK Investment Management LLC now owns 19,466,931 shares of the health services provider’s stock worth $1,404,150,000 after acquiring an additional 544,733 shares in the last quarter. Baillie Gifford & Co. grew its position in shares of Teladoc Health by 23.5% in the 4th quarter. Baillie Gifford & Co. now owns 10,877,063 shares of the health services provider’s stock worth $998,733,000 after acquiring an additional 2,071,756 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Teladoc Health by 17.1% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,140,808 shares of the health services provider’s stock worth $839,309,000 after buying an additional 1,336,508 shares in the last quarter. Nikko Asset Management Americas Inc. raised its position in shares of Teladoc Health by 18.2% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 8,755,058 shares of the health services provider’s stock worth $809,843,000 after purchasing an additional 1,349,776 shares during the period. Finally, Kinnevik AB publ purchased a new position in shares of Teladoc Health during the fourth quarter valued at $458,235,000. Hedge funds and other institutional investors own 87.17% of the company’s stock.

Teladoc Health Company Profile (Get Rating)

Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.

See Also

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.